See more : DNAPrint Genomics, Inc. (DNAG) Income Statement Analysis – Financial Results
Complete financial analysis of NeuroBo Pharmaceuticals, Inc. (NRBO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeuroBo Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Honeywell Automation India Limited (HONAUT.NS) Income Statement Analysis – Financial Results
- Here Media Inc. (HRDIL) Income Statement Analysis – Financial Results
- Suncor Energy Inc. (SU.TO) Income Statement Analysis – Financial Results
- Imperium Technology Group Limited (IPGGF) Income Statement Analysis – Financial Results
- Mangalam Drugs & Organics Limited (MANGALAM.BO) Income Statement Analysis – Financial Results
NeuroBo Pharmaceuticals, Inc. (NRBO)
About NeuroBo Pharmaceuticals, Inc.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 28.00K | 72.00K | 67.00K | 17.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -28.00K | -72.00K | -67.00K | -17.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.16M | 2.78M | 6.55M | 21.87M | 17.48M | 14.31M | 22.69M | 8.74M | 3.99M | 52.00K |
| General & Administrative | 6.73M | 8.64M | 8.75M | 7.85M | 2.70M | 8.49M | 60.00K | 5.96M | 3.18M | 214.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.38M | 0.00 | 0.00 | 0.00 |
| SG&A | 6.73M | 8.64M | 8.75M | 7.85M | 2.70M | 8.49M | 10.44M | 5.96M | 3.18M | 214.00K |
| Other Expenses | 0.00 | -83.00K | 0.00 | -1.00K | 12.15M | -178.00K | 10.44M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.89M | 11.42M | 15.30M | 29.72M | 20.18M | 22.81M | 33.12M | 14.70M | 7.17M | 266.00K |
| Cost & Expenses | 15.89M | 11.42M | 15.30M | 29.72M | 20.18M | 22.81M | 33.12M | 14.70M | 7.17M | 266.00K |
| Interest Income | 461.00K | 2.19K | 14.00K | 39.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 2.19M | 0.00 | 39.00K | 22.00K | 654.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.00K | 28.00K | 72.00K | 67.00K | 17.00K | 6.67M | 60.00K | -17.00K | 2.01M | -1.00K |
| EBITDA | -15.88M | -11.40M | -15.21M | -29.61M | -21.17M | -15.49M | -33.09M | -14.50M | -6.07M | -283.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -15.89M | -19.63M | -15.30M | -29.72M | -20.18M | -22.81M | -33.12M | -14.70M | -8.08M | -266.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.42M | 5.66M | 14.00K | 38.00K | -1.14M | -43.00K | -291.00K | 110.00K | -953.00K | -54.00K |
| Income Before Tax | -12.47M | -13.97M | -15.28M | -29.68M | -21.31M | -23.64M | -33.42M | -14.59M | -9.03M | -320.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.85M | -62.00K | -85.00K | 1.12M | 654.00K | 286.00K | -136.82K | -146.00K | 55.00K |
| Net Income | -12.47M | -6.12M | -15.22M | -29.59M | -22.43M | -23.64M | -33.42M | -14.59M | -9.03M | -320.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.46 | -19.01 | -157.85 | -437.95 | -1.03K | -166.80 | -2.42K | -1.88K | -1.28K | -45.27 |
| EPS Diluted | -2.46 | -19.01 | -157.85 | -437.95 | -1.03K | -166.80 | -2.42K | -1.88K | -1.28K | -45.27 |
| Weighted Avg Shares Out | 5.07M | 321.70K | 96.43K | 67.57K | 21.77K | 141.71K | 13.80K | 7.75K | 7.07K | 7.07K |
| Weighted Avg Shares Out (Dil) | 5.07M | 321.70K | 96.43K | 67.57K | 21.77K | 141.71K | 13.80K | 7.75K | 7.07K | 7.07K |
NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT
BOSTON , Aug. 14, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appointment of current Board member, Hyung Heon ("H.H.") Kim, as the Company's Chief Executive Officer...
NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Dosing of First Patient in Phase 2a Clinical Trial of DA-1241 Expected September 2023 Cash and Cash Equivalents of $28.7 Million, Expected to Fund the Company into 2024, Through Multiple Clinical Milestones BOSTON , Aug. 9, 2023 /PRNewswire/ -- NeuroBo...
NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
BOSTON , Aug. 3, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that it has received the first site Institutional Review Board (IRB) approval for Zeid Kayali,...
NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01
BOSTON , Aug. 2, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that it has entered into a term sheet with MThera Pharma Co., Ltd. (MTHERA) which provides...
10 Top Penny Stocks To Watch Right Now For Under $1
Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure.
7 Penny Stocks To Watch Right Now For Under $1
Have you ever dreamt of uncovering a hidden gem in the stock market, something that could turn your modest investment into a jackpot? Welcome to the world of penny stocks.
Here's Why NeuroBo Pharmaceuticals, Inc. (NRBO) Could be Great Choice for a Bottom Fisher
NeuroBo Pharmaceuticals, Inc. (NRBO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates...
Penny Stocks To Buy? 10 Under $1 To Watch This Week
Penny stocks under $1 to watch this week. The post Penny Stocks To Buy?
Penny Stocks To Buy? 7 Under $1 To Watch This Week
Penny stocks to watch trading for pennies this week. The post Penny Stocks To Buy?
Best Penny Stocks To Buy Before 2023? 4 To Watch Now
Penny stocks to watch this week with news before 2023. The post Best Penny Stocks To Buy Before 2023?
Source: https://incomestatements.info
Category: Stock Reports